Switch theme
Sign up to access all valuation multiples
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
2018
82
Last FY Revenue n/a
LTM EBITDA -$120M
-$96.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ventyx Biosciences has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$120M.
In the most recent fiscal year, Ventyx Biosciences achieved revenue of n/a and an EBITDA of -$147M.
Ventyx Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ventyx Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$120M | XXX | -$147M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$144M | XXX | -$148M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$135M | XXX | -$135M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ventyx Biosciences's stock price is $2.
Ventyx Biosciences has current market cap of $121M, and EV of -$96.9M.
See Ventyx Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$96.9M | $121M | XXX | XXX | XXX | XXX | $-1.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ventyx Biosciences has market cap of $121M and EV of -$96.9M.
Ventyx Biosciences's trades at n/a EV/Revenue multiple, and 0.7x EV/EBITDA.
Equity research analysts estimate Ventyx Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ventyx Biosciences has a P/E ratio of -0.9x.
See valuation multiples for Ventyx Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV (current) | -$96.9M | XXX | -$96.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.8x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVentyx Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
Ventyx Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ventyx Biosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ventyx Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | -26% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ventyx Biosciences acquired XXX companies to date.
Last acquisition by Ventyx Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Ventyx Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ventyx Biosciences founded? | Ventyx Biosciences was founded in 2018. |
| Where is Ventyx Biosciences headquartered? | Ventyx Biosciences is headquartered in United States of America. |
| How many employees does Ventyx Biosciences have? | As of today, Ventyx Biosciences has 82 employees. |
| Who is the CEO of Ventyx Biosciences? | Ventyx Biosciences's CEO is Dr. Raju S. Mohan, PhD. |
| Is Ventyx Biosciences publicy listed? | Yes, Ventyx Biosciences is a public company listed on NAS. |
| What is the stock symbol of Ventyx Biosciences? | Ventyx Biosciences trades under VTYX ticker. |
| When did Ventyx Biosciences go public? | Ventyx Biosciences went public in 2021. |
| Who are competitors of Ventyx Biosciences? | Similar companies to Ventyx Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ventyx Biosciences? | Ventyx Biosciences's current market cap is $121M |
| Is Ventyx Biosciences profitable? | Yes, Ventyx Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ventyx Biosciences? | Ventyx Biosciences's last 12 months EBITDA is -$120M. |
| What is the current EV/EBITDA multiple of Ventyx Biosciences? | Current EBITDA multiple of Ventyx Biosciences is 0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
